Is Family Care overvalued or undervalued?

As of 24 October 2025, the valuation grade for Family Care has moved from fair to expensive. Based on the analysis, the company is currently overvalued. Key ratios indicate this, with a PE Ratio of 0.82, an EV to EBITDA of 0.98, and an ROE of 219.63%.
In comparison to its peers, Family Care's valuation metrics are significantly lower than those of Max Healthcare, which has a PE of 95.69, and Apollo Hospitals, with a PE of 71.66. The stark contrast in valuation suggests that Family Care is not only overvalued but also underperforming relative to its peers. Additionally, the company's stock has underperformed against the Sensex, with a YTD return of -32.88% compared to the Sensex's 7.77%, reinforcing the overvaluation narrative.